The VeriSeq™ NIPT solution from Illumina is a powerful screening test that can provide information on the health of a developing fetus using a simple maternal blood draw. Cell-free DNA, released by placental cells during pregnancy, can be used to test for selected chromosomal abnormalities in the fetus as early as 10 weeks’ gestation. Find out how this NIPT workflow detects aneuploidy in three simple steps.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2017.